MAP4K5 (Gene)

Synonyms:ENTREZ:11183, GCKR, HGNC:6867, KHS, KHS1, MAP4K5, MAPKKKK5, MIM:604923, NM_006575, NM_198794, NP_006566, NP_942089, XM_006720013, XM_011536377, XM_011536378, XM_011536379, XM_011536380, XM_024449461, XP_006720076, XP_011534679, XP_011534680, XP_011534681, XP_011534682, XP_024305229, mitogen-activated protein kinase kinase kinase kinase 5
Omim:OMIM:604923
Id:ENSG00000012983
Hgnc:HGNC:6867
Entrez:11183
Description:mitogen-activated protein kinase kinase kinase kinase 5
This gene encodes a member of the serine/threonine protein kinase family, that is highly similar to yeast SPS1/STE20 kinase. Yeast SPS1/STE20 functions near the beginning of the MAP kinase signal cascades that is essential for yeast pheromone response. This kinase was shown to activate Jun kinase in mammalian cells, which suggested a role in stress response. Two alternatively spliced transcript variants encoding the same protein have been described for this gene. [provided by RefSeq, Jul 2008]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View MAP4K5's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with MAP4K5.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using MAP4K5.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for MAP4K5.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with MAP4K5.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.